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Abstract
Background: The overall incidence of Pneumocystis jirovecii pneumonia (PJP) in solid organ transplant recipients is 5–15%.
A timely diagnosis of PJP is difficult and relies on imaging and detection of the organism.
Methods: We present a case series of four patients displaying hypercalcaemia with an eventual diagnosis of PJP and docu-
ment the management of the outbreak with a multidisciplinary team approach. We discuss the underlying pathophysiology
and previous reports of hypercalcaemia preceding a diagnosis of PJP. We also reviewed the evidence concerning PJP diagno-
sis and treatment.
Results: Within our renal transplant cohort, four patients presented within 7 months with hypercalcaemia followed by an
eventual diagnosis of PJP. We measured their corrected calcium, parathyroid hormone (PTH), 1,25-dihydroxycholecalciferol
[1,25-(OH)2D3] and 25-hydroxycholecalciferol [25(OH)D] levels at admission and following treatment of PJP. All four patients
diagnosed with PJP were 4–20 years post-transplantation. Three of the four patients demonstrated PTH-independent hyper-
calcaemia (corrected calcium >3.0 mmol/L). The presence of high 1,25(OH)2D3 and low 25(OH)D levels suggest negation of
the negative feedback mechanism possibly due to an extrarenal source; in this case, the alveolar macrophages. All four
patients had resolution of their hypercalcaemia after treatment of PJP.
Conclusions: Given the outbreak of PJP in our renal transplant cohort, and based on previous experience from other units
nationally, we implemented cohort-wide prophylaxis with trimethoprim–sulphamethoxazole for 12 months in consultation
with our local infectious diseases unit. Within this period there have been no further local cases of PJP.
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Background
Pneumocystis jirovecii is a human-specific ascomycetous fungal
organism discovered in the 1900s [1]. Pneumocystis infection is
thought to involve aerosolized particle transmission [1].
Pneumocystis colonization may not manifest clinically in immu-
nocompetent humans [1, 2], yet in an immunocompromised
patient, Pneumocystis has lung tropism and can cause opportun-
istic pneumonia [1, 2].
In renal transplant recipients (RTRs), the incidence of P. jirovecii
pneumonia (PJP) is 5–15% in patients without prophylaxis, with a
greater relative risk up to 6 months post-transplant [3, 4].
Mortality rates are 13–38% in this population [5]. Cytomegalovirus
(CMV) infection, glucocorticoid use and recurrent rejection are
independent risk factors for PJP [6, 7]. Trimethoprim–sulphame-
thoxazole (TMP-SMX) prophylaxis [8] is recommended for 3–
6 months post-transplant [9–11], which is when most infections
occur [3, 10]. Beyond the first year post-transplant, risk factors for
PJP include increased levels of immunosuppression [12], allograft
rejection and abnormal renal function [13].
While PJP in RTRs is relatively uncommon, recent PJP out-
breaks in Australian renal transplant units [9, 14] have
refocused attention on the current evidence behind PJP prophy-
laxis. An uncommon feature of PJP is hypercalcaemia, often
preceding radiographic findings [15–21]. We present four RTRs
with hypercalcaemia refractory to medical management pre-
ceding the diagnosis of PJP. We hypothesize that PJP contributed
to the preceding hypercalcaemia in three of the cases.
Biochemical and haematological results are summarized in
Table 1. Immunosuppression post-transplant and at diagnosis
are recorded in Table 2. The trend of hypercalcaemia is depicted
in Figure 1.
Case 1 (January 2014)
A 45-year-old restaurant worker with a living-related ABO-
incompatible renal transplant 4 years prior presented with exer-
tional dyspnoea and hypercalcaemia of 3.43 mmol/L. She had
6 months of TMP-SMX prophylaxis post-transplant. She was on
tacrolimus, mycophenolate and prednisolone without vitamin
D or calcium supplementation at presentation (Tables 1 and 2).
She previously had CMV viraemia (treated with currently unde-
tectable levels) and cellular-mediated graft rejection (diagnosed
November 2011). This was treated with pulsed methylpredniso-
lone and increased immunosuppression. A biopsy post-
treatment showed no further rejection. Bactrim was not
restarted during treatment for graft rejection.
Auscultation revealed fine crackles bilaterally and she was
afebrile. Her parathyroid hormone (PTH)-independent hypercal-
caemia (PTH<0.32 pmol/L) remained high after intravenous
crystalloids and calcitonin. Bisphosphonates were avoided due
to impaired renal function (creatinine 258 mmol/L). Other tests
showed elevated 1,25-dihydroxycholecalciferol [1,25(OH)2D3]
450 pmol/L, low 25-hydroxycholecalciferol [25(OH)D] 28 nmol/L,
serum angiotensin-converting enzyme (ACE) 37.7 U/L and PTH-
related protein of 2.7 pmol/L. She was not leucopenic on
admission.
Chest x-Ray (CXR) showed interstitial infiltrates. A high-
resolution CT scan of the chest (HRCT) showed ground-glass
opacities bilaterally. TMP-SMX was commenced at the treat-
ment dose for presumed PJP. Bronchoalveolar lavage (BAL)
revealed P. jirovecii on polymerase chain reaction (PCR) testing.
Following PJP treatment, she recovered and her serum corrected T
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calcium and PTH improved to 2.2 mmol/L and 11 pmol/L, respec-
tively, on discharge (Table 1, Figure 1).
Case 2 (March 2014)
A 57-year-old policeman with a deceased-donor renal trans-
plant 11 years before with no previous allograft rejection pre-
sented with exertional dyspnoea over the preceding month. He
was on mycophenolate and prednisolone without vitamin D or
calcium supplementation (Tables 1 and 2). Auscultation
revealed bilateral fine crackles and he was afebrile.
At presentation, he had PTH-independent hypercalcaemia
(corrected calcium 3.04 mmol/L, PTH<0.32 pmol/L) with acute-
on-chronic renal failure (creatinine 208 mmol/L from a baseline
of 170 mmol/L in 2013). Other tests showed 1,25(OH)2D3
of 588 pmol/L, PTH-related protein <2.0 pmol/L and serum
ACE<5.0 U/L. Serum protein electrophoresis and urine electro-
phoresis were normal. An HRCT showed diffuse ground-glass
changes. BAL was negative for P. jirovecii oocysts and other
infections.
Management with intravenous fluids, increased predniso-
lone dose and intravenous bisphosphonate was commenced.
His dyspnoea improved and his corrected calcium improved to
2.89 mmol/L and PTH to 4.04 pmol/L at discharge. He was read-
mitted the following week with worsening dyspnoea and per-
sisting hypercalcaemia of 3.19 mmol/L. He had a normal
transthoracic echocardiogram and a negative septic screen, but
a repeat HRCT showed worsening ground-glass infiltrates. A
repeat bronchoscopy revealed P. jirovecii PCR positive on BAL.
TMP-SMX was commenced; this was briefly changed to atova-
quone while his renal function recovered. At discharge, his cor-
rected calcium and PTH were 2.53 mmol/L and 5.6 pmol/L,
respectively (Table 1, Figure 1).
Case 3 (May 2014)
A 45-year-old woman with a living-related renal transplant 30
years before presented with worsening exertional dyspnoea.
Her comorbidities included ischaemic heart disease and no
previous allograft rejection. She was on mycophenolate and
prednisolone as well as vitamin D and calcitriol (Tables 1 and 2).
Auscultation revealed fine crackles, worse on the left, and she
was afebrile.
A CXR was clear. Empirical treatment for presumed atypical
pneumonia with ceftriaxone and azithromycin was started. An
HRCT showed ground-glass opacities bilaterally. She was hyper-
calcaemic (corrected calcium 3.05 pmol/L) and had renal failure
(creatinine 455 mmol/L). Other tests showed serum ACE<5.0 U/L,
serum PTH of 2.38 pmol/L and a normal serum/urine electro-
phoresis and autoimmune screen. Viral PCR on blood was posi-
tive for CMV. Induced sputum was tested for PJP PCR. Calcitriol
and vitamin D were ceased.
Septic shock necessitated intensive care unit (ICU) admis-
sion and intubation while awaiting a bronchoscopy. A broad-
spectrum antibiotic (piperacillin-tazobactam) was started. PJP
PCR from admission was positive and intravenous TMP-SMX
was commenced. Intravenous ganciclovir for CMV viraemia was
withheld, as she clinically improved. She was extubated and
discharged from the ICU after 3 days; however, her renal func-
tion continued to deteriorate, necessitating dialysis.
Respiratory distress prompted a return to the ICU for re-
intubation. Antibiotics were changed to meropenem and doxy-
cycline, while intravenous TMP-SMX was continued.
Bronchoscopy was negative for P. jirovecii but positive for CMVT
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PCR (titre 9471 copies/mL). Intravenous ganciclovir was added.
Meropenem and doxycycline were ceased after 8 days while
ganciclovir and TMP-SMX were continued (14 and 21 days,
respectively). She returned to the ward after an 18-day ICU stay.
Prophylactic oral valganciclovir and oral TMP-SMX were com-
menced after her initial treatment. Her corrected calcium was
2.48mmol/L on discharge (Table 1, Figure 1). She remained dialy-
sis dependent.
Case 4 (July 2014)
A 52-year-old salesman with a deceased-donor renal transplant
6 years before with no previous allograft rejection was admitted
with worsening exertional dyspnoea. He had pre-existing pri-
mary hyperparathyroidism with a subtotal parathyroidectomy
in 2004. Subsequent PTH levels were 10–44 pmol/L. He was on
tacrolimus, mycophenolate and prednisolone as well as calci-
triol (Tables 1 and 2). Respiratory examination was unremark-
able and he was afebrile.
Treatment for presumed atypical pneumonia with ceftriax-
one and azithromycin was commenced after a normal CXR and
septic screen. His corrected calcium was 2.68 mmol/L. Other
tests showed PTH of 18.8 pmol/L, 1,25(OH)2D3 of 75 pmol/L,
serum creatinine of 159 mmol/L and serum ACE of 29.4 U/L. An
HRCT showed small patchy areas of ground-glass opacity. Other
viral PCRs, including CMV, were negative. Calcitriol was ceased.
Given our prior cases, we started TMP-SMX at a lower dose
in consultation with the infectious diseases unit. A broncho-
scopy was done 3 days after starting TMP-SMX, as he failed to
improve. This was negative for fungi, tuberculosis, bacteria and
PJP PCR; however, PJP PCR from an induced sputum sample on
admission returned positive. He was commenced on TMP-SMX
at the treatment dose with a brief change to atovaquone for
renal impairment. Interestingly, his hypercalcaemia had peaked
and returned to normal (corrected calcium 2.49 mmol/L) pre-
bronchoscopy (Table 1, Figure 1).
PJP outbreak
At the time of the outbreak, our transplant cohort consisted of
146 RTRs (80 public RTRs and 66 RTRs with private follow-up).
With no previous cases in our renal transplant cohort, the case
series represented an outbreak of PJP as defined by the World
Health Organization (WHO) [22]. After Cases 1 and 2 were identi-
fied, a working group (comprising the nephrology, infectious
diseases, respiratory and physiotherapy departments) was
formed with the aims of early recognition of at-risk patients,
institution of universal prophylaxis and minimizing patient-to-
patient transmission. Outbreak management was developed
according to Phipps et al. [14].
Contact tracing identified our outpatient waiting area for
public RTRs as a source of transmission. A protocol (Figure 2)
involving induced sputum testing, CXR and HRCT was designed
to screen all 80 public RTRs for signs and symptoms of PJP. To
minimize further transmission, public RTRs were designated
their own waiting room and N95 masks were provided to
patients with respiratory symptoms. An isolation room staffed
by physiotherapists was designated for induced sputum testing,
which was fast-tracked by the pathology laboratory. RTRs were
invited to appointments where they were given information
about the PJP outbreak. RTRs with respiratory symptoms
received a CXR and induced sputum testing, with progression to
HRCT if any infiltrates were present.
All public RTRs were commenced on a 6-month course of
TMP-SMX at a prophylactic dose of 160/800 mg half-tablet daily
and adjusted for renal function. This was empirically extended
to 1 year based on previous experience [14] of new infections
within a 6-month prophylaxis period. Throughout this period,
eight patients were intolerant of TMP-SMX and received alter-
native agents. The major side effect of TMP-SMX in our cohort
was a transient increase in serum creatinine that resolved on
cessation of TMP-SMX. Cases 3 and 4 presented to the hospital
Fig. 2. Pathway used to contain outbreak in our renal transplant cohort.
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before starting prophylaxis. In all four cases, treatment of PJP
with TMP-SMX was dosed at TMP 15–20 mg/kg/day and SMX
75–100 mg/kg/day in three divided doses for 3 weeks with dose
adjustment for renal impairment. Private RTRs were not
exposed (private rooms located in another building) and were
therefore excluded from cohort prophylaxis. None of these
patients were ultimately infected with PJP.
Discussion
Hypercalcaemia and PJP
PJP was originally described as a reactivation of latent infection
acquired during childhood; however, current evidence points
towards de novo infection from environmental sources and
infected individuals as other methods of transmission [23, 24].
Five case reports [15–20] and one case series [21] describe similar
presentations of hypercalcaemia in RTRs eventually leading to a
diagnosis of PJP. The underlying pathophysiology has been linked
with alveolar macrophage activity in PJP clearance [25, 26].
There is a high prevalence of hypercalcaemia after renal
transplant (up to 25% in the first year post-transplant [27]),
which was reflected in our cohort (21.6% at the time of the out-
break). Our cases had relatively normal corrected calcium levels
post-transplant (Table 1). At presentation, only Cases 3 and 4
were on calcium and/or vitamin D supplementation, which may
have potentiated hypercalcaemia. Cases 1, 2 and 3 had signifi-
cant PTH-independent hypercalcaemia (corrected cal-
cium>3.0 mmol/L) that was resistant to medical management.
Case 4 technically had primary hyperparathyroidism causing
hypercalcaemia, however, he was included as part of the PJP
outbreak. With increased 1,25-(OH)2D3 levels, we postulate
increased hydroxylation via 25-hydroxyvitamin D 1-alpha
hydroxylase from alveolar macrophages could be responsible
for the hypercalcaemia [28]. While negative feedback of this
enzyme usually occurs in hypercalcaemia, extra-renal synthesis
and metabolism of 1,25-(OH)2D3 is less tightly regulated by PTH
and calcium, and calcium intake does not lower serum 1,25-
(OH)2D3 in such patients [29]. Increased 1,25-(OH)2D3 production
by alveolar macrophages occurs in sarcoidosis [28–31], and a
similar process has been demonstrated post-nephrectomy [32].
The high 1,25-(OH)2D3 levels were present in Cases 1, 2 and 4 (no
results were recorded for Case 3). Low 25-(OH)D levels were
present in Cases 1 and 4 [Cases 2 and 3 were taking cholecalci-
ferol at the time of diagnosis, contributing to a high 25-(OH)D
level]. The low 25-(OH)D levels may have been caused by
ongoing 1-alpha hydroxylation with consumption of 25-(OH)D.
The eventual normalization of 1,25-(OH)2D3 could correlate with
decreased alveolar macrophage activity with treatment of PJP.
However, low 25-(OH)D levels are also common post-
transplantation [33] for various reasons [34] including renal
impairment and increased levels of fibroblast growth factor 23.
1,25-(OH)2D3 production in vitro has been demonstrated in
pulmonary alveolar macrophages (PAMs) from patients with
sarcoidosis [30]. A similar response occurs with normal PAMs
incubated with recombinant human interferon-gamma; how-
ever, exogenous 1,25-(OH)2D3 was able to decrease endogenous
hormone production in normal PAMs to a greater degree than in
sarcoid PAMs [31]. The increased ability of sarcoid PAMs to
produce 1,25-(OH)2D3 compared with normal PAMs has been
documented in other granulomatous diseases [35] but has not
been studied at a molecular level in infections such as PJP.
Hypercalcaemia associated with elevated 1,25(OH)2D3 has also
been documented in fungal infections in immunocompromised
patients (Cryptococcus and Coccidioides) [36, 37].
PJP prophylaxis regimens, risk factors and difficulties in
diagnosis
Our case series illustrates that PJP can present late post-
transplant. It also raises the question of the optimal duration of
PJP prophylaxis post-transplant and the efficacy of TMP-SMX as
prophylaxis. Prevention is important, as PJP presentations are
difficult to differentiate from other respiratory infections [1], as
seen in our series. Cases 3 and 4 in particular highlight how PJP
can be misdiagnosed as atypical pneumonia. Further diagnostic
issues include direct microscopy being less sensitive in HIV-
negative patients [38] and PCR being positive in patients
colonized with P. jirovecii [39]. While new methods of diagnosing
PJP are being developed [39, 40], PJP diagnosis remains reliant on
the correlation of clinical and radiological findings with micro-
biological investigations [1].
While PJP usually occurs within the first year post-
transplant [3, 4, 15, 17, 19, 21], presentations up to 17–40 months
post-transplant have been noted (5, 41–45). In these groups, risk
factors of PJP included early discontinuation of TMP-SMX pro-
phylaxis within the first year post-transplant (or complete lack
of prophylaxis), number and type of rejection treatments, age
65 years, lymphocyte count<750/mm3 and CMV infection.
The use of mycophenolate mofetil was also a risk factor [46]. In
our cohort, only Case 1 had previous allograft rejection preced-
ing PJP diagnosis. Our unit policy at the time did not include
restarting PJP prophylaxis during rejection treatment. Regarding
age as a risk, all our patients were <65 years [45]. Cases 1–3 had
varying levels of renal impairment at diagnosis; a risk factor
identified by Eitner et al. [13]. All cases had a minimum of
6 months TMP-SMX prophylaxis post-transplantation. Case 1
had prior CMV viraemia that was treated (viral load<400 copies/
mL at PJP outbreak). None of our cases were lymphopaenic at
presentation (Table 2).
The dosage and type of immunosuppression may also influ-
ence the risk of PJP [13, 47–49]. Increased immunosuppression
during rejection treatment increases PJP risk [13]. Retrospective
studies highlight high-dose corticosteroids over a prolonged
period [47] and tacrolimus-based regimens [48] (compared with
cyclosporin) as causing a higher PJP incidence. The US Renal
Data System (USRDS) cohort showed no association between
induction immunosuppression levels and PJP risk, but did show
that regimens containing sirolimus were associated with PJP
infection [49]. None of our cases were on sirolimus. At trans-
plantation, Cases 1, 2 and 4 had standard immunosuppression
doses that were decreased to appropriately lower levels at the
time of diagnosis. Case 3 had a lower immunosuppression dose
at transplantation and Cases 2 and 3 had ceased tacrolimus and
were only on mycophenolate and prednisolone at presentation
(Table 2).
The recommended duration of PJP prophylaxis is
3–12 months after solid organ transplantation [9]. The Kidney
Disease: Improving Global Outcomes (KDIGO) 2009 clinical prac-
tice guidelines recommend 3–6 months post-transplant prophy-
laxis, and at least 6 weeks during and after treatment for acute
rejection [50]. The European Best Practice guidelines recom-
mend at least 4 months of prophylaxis post-transplant, with a
further 3–4 months of prophylaxis during rejection [11]. There is
worldwide variation in the use of TMP-SMX prophylaxis [5, 41]
with PJP outbreaks in Japan, the UK and Switzerland occurring
in units that did not offer routine PJP prophylaxis [51].
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No prophylaxis following heart, liver and kidney–pancreas
transplant was associated with a higher incidence of PJP com-
pared with either a low-dose or high-dose TMP-SMX prophy-
laxis regimen [52].
There was no difference in PJP incidence between the low-
dose TMP-SMX (80/400 mg/day or 160/800 mg/alternate days)
and high-dose TMP-SMX (160/800 mg/day) groups. Second-line
prophylaxis options include dapsone, atovaquone and pentami-
dine. Dapsone [53] and atovaquone [54] have been compared
with TMP-SMX in two separate retrospective case-matched
studies of RTRs, with no PJP cases documented in either arm
over a 12-month period. In the dapsone study, a higher rate of
infections occurred in the dapsone group, while in the atova-
quone study, patients on TMP-SMX prophylaxis had a higher
rate of treatment discontinuation due to adverse events.
Six months has been suggested as the optimal duration of
PJP prophylaxis post-transplant, as it correlates with the esti-
mated median incubation period of PJP (53 days with a range of
7–188 days) [55]. Without randomized controlled trial evidence
for both PJP prophylaxis and treatment in RTRs [24], current pro-
phylaxis guidelines such as from KDIGO are the best guide and
are certainly preferable to no prophylaxis [5]. While previous
reviews mention treatment of PJP outbreaks with TMP-SMX and
instituting universal prophylaxis in RTRs, prophylaxis duration
from that point on is unclear [41–42, 44]. Post-PJP outbreak,
Phipps et al. [14] and Mitsides et al. [56] instituted a 12-month
TMP-SMX prophylaxis regimen across their transplant cohorts,
with no further cases diagnosed apart from patients who were
not compliant with prophylaxis.
In total, 83 cases of PJP occurred in Australia from 2010 to
2012, comprising a total of 14 outbreaks, with the majority being
in RTRs [9]. Our case series adds to the literature of hypercalcae-
mia presenting as a feature of PJP in the renal transplant popu-
lation and demonstrates the need for ongoing vigilance against
post-transplant infections and minimizing the risk factors
thereof. We highlight the importance of a multidisciplinary
approach in managing an outbreak. Measures such as contact
tracing and a 12-month prophylaxis strategy were important in
limiting further infections. To date, there have been no further
PJP cases in this cohort. We have also instituted PJP prophylaxis
in patients treated for graft rejection as part of our unit policy.
Conclusion
In conclusion, we submit that hypercalcaemia of an unclear
aetiology and refractory to treatment in a renal transplant recip-
ient can be a feature of impending PJP. An early bronchoscopy is
essential to aid the diagnosis. Early recognition and cohort pro-
phylaxis for 12 months is a proven strategy that can limit PJP
progression, with a multidisciplinary approach representing a
crucial component of any outbreak containment strategy.
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